Neoleukin Therapeutics (NLTX) Prices 8.925M Share Offering at $8.40/Sh

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. DFTX
6. GOOGL
7. APGE
8. MU
9. HOOD
10. ABBV

Go back to Neoleukin Therapeutics (NLTX) Prices 8.925M Share Offering at $8.40/Sh

After-Hours Movers 12/17: (SCS) (CTAS) (NE) Higher; (FIXX) (PACB) (FDX) Lower (more...)

December 17, 2019 6:00 PM EST

Today's After-Hours Movers

Homology Medicines, Inc. (NASDAQ: FIXX) 20.2% LOWER; announced today promising initial clinical data from the first gene therapy clinical trial in phenylketonuria (PKU). The pheNIX trial is a Phase 1/2 randomized, concurrently controlled, dose-escalation study for adults with PKU. As of December 2, 2019, two patients had received investigational HMI-102 gene therapy in Cohort 1 (low-dose) and one patient in Cohort 2 (mid-dose). Preliminary safety data from Cohorts 1 and 2 showed HMI-102 was well-tolerated. Efficacy data from the first patient in Cohort 2 indicated a dose-response effect with an observed reduction in... More

Neoleukin Therapeutics (NLTX) Announces Proposed $50M Public Offering of Common Stock

December 17, 2019 4:38 PM EST

(Updated - December 17, 2019 4:39 PM EST)

Neoleukin Therapeutics, Inc. (Nasdaq: NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that it intends to offer and sell, subject to market and other conditions, up to $50.0 million of shares of its common stock in an... More